Most Read Articles
15 Sep 2016
Tigecycline therapy produces favourable outcomes in severe Clostridium difficile infection (sCDI), says a study.
Roshini Claire Anthony, 22 May 2018

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Pearl Toh, 28 Dec 2017
The addition of low oxygen levels measured by pulse oximetry to the three signs delineated in the current diagnostic model for pneumonia in primary care setting derived by van Vugt, which include fever, tachycardia, and crackly breath sounds on auscultation, can add value to diagnostic precision and help general practitioners (GPs) differentiate pneumonia from less serious infections, a study suggests.
26 Sep 2017
Ceftazidime-avibactam appears to offer a reasonable alternative to colistin in the treatment of Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) infections, according to a study.

Metformin a promising adjunctive, host-therapy in diabetic patients with TB

06 Nov 2017

Metformin may improve survival during tuberculosis (TB) treatment in patients with diabetes mellitus—a condition which particularly carries an increased risk of adverse TB treatment outcomes, a study has found.

The retrospective cohort study included 2,416 patients aged >13 years who were undergoing treatment for culture-confirmed, drug susceptible pulmonary TB. Assessments included the effect of diabetes on mortality during TB treatment, sputum culture conversion at 2 months, as well as the effect of metformin on survival during TB treatment.

Among the patients, those with diabetes had greater odds of death during anti-TB therapy (odds ratio [OR], 1.91; 95 percent CI, 1.51 to 2.40) and of remaining culture-positive at 2 months (OR, 1.72; 1.25 to 2.38). These results were adjusted for age, sex, chronic kidney disease, cancer, hepatitis C, tobacco use, cavitary disease and treatment adherence.

Importantly, the use of metformin in patients with diabetes led to a significant reduction in mortality during anti-TB therapy (hazard ratio, 0.56; 0.39 to 0.82). Mortality was similar between metformin users and patients without diabetes.

In light of the improved survival associated with metformin, researchers pointed out the potential role of the glucose-lowering drug as an adjunctive, host-directed therapy in diabetic patients with TB.

Diabetes mellitus has been shown to be an important risk factor for TB, affecting disease presentation and treatment response. Additionally, the infectious disease may induce glucose intolerance and worsen glycaemic control in diabetic patients. [Lancet Infect Dis 2009;9:737–46]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Sep 2016
Tigecycline therapy produces favourable outcomes in severe Clostridium difficile infection (sCDI), says a study.
Roshini Claire Anthony, 22 May 2018

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Pearl Toh, 28 Dec 2017
The addition of low oxygen levels measured by pulse oximetry to the three signs delineated in the current diagnostic model for pneumonia in primary care setting derived by van Vugt, which include fever, tachycardia, and crackly breath sounds on auscultation, can add value to diagnostic precision and help general practitioners (GPs) differentiate pneumonia from less serious infections, a study suggests.
26 Sep 2017
Ceftazidime-avibactam appears to offer a reasonable alternative to colistin in the treatment of Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) infections, according to a study.